Belgium-based UCB hit the mark in the company’s Phase III clinical trial assessing zilucoplan as a potential treatment for adults with generalized myasthenia gravis, a rare autoimmune disease. Vanda Pharmaceuticals’ late-stage study of tradipitant as a treatment for the symptoms of gastroparesis, a digestive disorder, failed to meet the trial’s primary endpoint.
The Epidemic of Obesity and its Impact on the Immune System
Business, Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Disease 2019 (COVID-19), Diet, Epidemics, Health, Immune System, Malnutrition, National Institute of Environmental Health Sciences (NIEHS), Obesity, Peptides, Pharma, Public Health Crisis, R&D, Therapeutics, Weight Loss, World Health OrganizationWhile food shortage and malnutrition have been a common scenario throughout human history, the worldwide public health crisis caused by the epidemic of obesity is relatively recent.
Research Roundup: Link Between Herpes Simplex Virus and Neurogenerative Diseases Gets More Support
Alzheimer’s disease, Clinical Trials, COVID-19 booster shots, Dementia, Herpes Simplex Virus, Medical Journals, Molecules, Multiple Sclerosis, Myelin, Nature Communications, Neurogenerative diseases, Peptides, Proteins, R&D, Rice University, The Lancet, University of Houston, University of Illinois at ChicagoResearchers at the University of Illinois at Chicago published what they are calling a “first of its kind study” that found a possible direct link between neurodegenerative diseases and the herpesvirus.
An experimental Alzheimer’s drug from Roche and AC Immune failed to slow cognitive and functional decline in a clinical trial, the Swiss companies said, in a fresh setback to efforts to fight the fatal dementia-causing disease.
Critically ill Covid-19 patients recovered rapidly from respiratory failure after three days of treatment with RLF-100, a therapy granted fast-track designation in the United States, two drug companies said on Sunday.
Japanese drug-discovery company PeptiDream Inc. will collaborate with Merck & Co. in developing COVID-19 therapies.
Ligandal is reportedly the only company developing a prospective “antidote” and vaccine in a single platform for COVID-19, with an approach that could actually help eliminate the virus from an already-infected host, while also bolstering the immune response.
BioSpace Global Roundup, March 26
Antibodies, Business, Clinical Trials, Consortium, Coronavirus Disease (COVID-19) Pandemic, European Medicines Agency (EMA), European Patent Office, FDA/Regulatory, Immuno-oncology, Immunotherapeutics, Messenger RNA (mRNA) Vaccines, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Peptides, R&D, Vaccines, X-raysA recap of business developments from life sciences companies around the world, including U.K.-based Vaccitech Limited and the University of Oxford touting positive safety and efficacy trends in a mid-stage prostate cancer study.
Harmony Biosciences snagged approval from the U.S. FDA for the company’s first commercial product, a treatment for narcolepsy.
Merck agreed to acquire Tilos, a privately held biopharma company developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases.